Skip to main content
Erschienen in: European Archives of Oto-Rhino-Laryngology 11/2015

01.11.2015 | Head and Neck

Assessment of caroverine as a potential chemotherapeutical agent in HNSCC cell lines

verfasst von: Georg Haymerle, Dietmar Thurnher, Lorenz Kadletz, Isabella Stanisz, Markus Brunner, Ulana Kotowski, Elisabeth Enzenhofer, Gregor Heiduschka

Erschienen in: European Archives of Oto-Rhino-Laryngology | Ausgabe 11/2015

Einloggen, um Zugang zu erhalten

Abstract

Since the prognosis of head and neck squamous cell carcinoma (HNSCC) still remains poor, identifying novel chemotherapeutic agents is of outmost importance. The anticancer potential of quinoxalines has been described in various tumor entities. Caroverine, also a quinoxaline derivative, has been shown to suppress tumor promotion factors. The aim of this study was to evaluate the effect of caroverine on HNSCC cell lines. The HNSCC cell lines SCC9, SCC25, CAL27, and FaDu were incubated with caroverine alone or in combination with cisplatin, 5-fluorouracil (5-FU) or cetuximab. Cell viability was measured using the CCK-8 assay. The murine 3T3 fibroblast cell line was used to address tissue specificity. Apoptosis was visualized by immunohistochemistry. Caroverine showed a dose-dependent growth inhibition in all cell lines, IC50 values ranged from 75.69 to 179.80 µM. This effect was increased when caroverine was combined with cetuximab or 5-FU. Immunohistochemistry displayed more apoptosis after caroverine treatment compared to controls. Furthermore, caroverine alone had no growth inhibitory effect on 3T3 cells. For the first time, this study provides evidence that caroverine may serve as a supportive drug in the treatment of HNSCC patients.
Literatur
1.
Zurück zum Zitat Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90CrossRefPubMed Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90CrossRefPubMed
2.
Zurück zum Zitat Leemans CR, Braakhuis BJM, Brakenhoff RH (2011) The molecular biology of head and neck cancer. Nat Rev Cancer 11:9–22CrossRefPubMed Leemans CR, Braakhuis BJM, Brakenhoff RH (2011) The molecular biology of head and neck cancer. Nat Rev Cancer 11:9–22CrossRefPubMed
3.
Zurück zum Zitat Moarbess G, Deleuze-Masquefa C, Bonnard V et al (2008) In vitro and in vivo anti-tumoral activities of imidazo[1,2-a]quinoxaline, imidazo[1,5-a]quinoxaline, and pyrazolo[1,5-a]quinoxaline derivatives. Bioorg Med Chem 16:6601–6610CrossRefPubMed Moarbess G, Deleuze-Masquefa C, Bonnard V et al (2008) In vitro and in vivo anti-tumoral activities of imidazo[1,2-a]quinoxaline, imidazo[1,5-a]quinoxaline, and pyrazolo[1,5-a]quinoxaline derivatives. Bioorg Med Chem 16:6601–6610CrossRefPubMed
4.
Zurück zum Zitat Ingle R, Marathe R, Magar D, Patel HM, Surana SJ (2013) Sulphonamido-quinoxalines: search for anticancer agent. Eur J Med Chem 65:168–186CrossRefPubMed Ingle R, Marathe R, Magar D, Patel HM, Surana SJ (2013) Sulphonamido-quinoxalines: search for anticancer agent. Eur J Med Chem 65:168–186CrossRefPubMed
5.
Zurück zum Zitat Udilova N, Kozlov AV, Bieberschulte W, Frei K, Ehrenberger K, Nohl H (2003) The antioxidant activity of caroverine. Biochem Pharmacol 65:59–65CrossRefPubMed Udilova N, Kozlov AV, Bieberschulte W, Frei K, Ehrenberger K, Nohl H (2003) The antioxidant activity of caroverine. Biochem Pharmacol 65:59–65CrossRefPubMed
6.
Zurück zum Zitat Nohl H, Bieberschulte W, Dietrich B, Udilova N, Kozlov AV (2003) Caroverine, a multifunctional drug with antioxidant functions. BioFactors 19:79–85CrossRefPubMed Nohl H, Bieberschulte W, Dietrich B, Udilova N, Kozlov AV (2003) Caroverine, a multifunctional drug with antioxidant functions. BioFactors 19:79–85CrossRefPubMed
7.
Zurück zum Zitat König P, Conca A, Lugmayer B (1999) Does a glutamate receptor blocker (Caroverine) enhance haloperidol in the treatment of schizophrenia? Neuropsychobiology 40:140–141CrossRefPubMed König P, Conca A, Lugmayer B (1999) Does a glutamate receptor blocker (Caroverine) enhance haloperidol in the treatment of schizophrenia? Neuropsychobiology 40:140–141CrossRefPubMed
8.
Zurück zum Zitat Saletu B, Grünberger J, Anderer P, Linzmayer L, König P (1995) Acute central effects of the calcium channel blocker and antiglutamatergic drug caroverine. Double-blind, placebo-controlled, EEG mapping and psychometric studies after intravenous and oral administration. Arzneimittelforschung 45:217–229PubMed Saletu B, Grünberger J, Anderer P, Linzmayer L, König P (1995) Acute central effects of the calcium channel blocker and antiglutamatergic drug caroverine. Double-blind, placebo-controlled, EEG mapping and psychometric studies after intravenous and oral administration. Arzneimittelforschung 45:217–229PubMed
9.
Zurück zum Zitat Nohl H, Rohr-Udilova N, Gille L, Bieberschulte W, Jurek D, Marian B, Schulte-Hermann R (2005) Ubiquinol and the papaverine derivative caroverine prevent the expression of tumour- promoting factors in adenoma and carcinoma colon cancer cells induced by dietary fat. BioFactors 25:87–95CrossRefPubMed Nohl H, Rohr-Udilova N, Gille L, Bieberschulte W, Jurek D, Marian B, Schulte-Hermann R (2005) Ubiquinol and the papaverine derivative caroverine prevent the expression of tumour- promoting factors in adenoma and carcinoma colon cancer cells induced by dietary fat. BioFactors 25:87–95CrossRefPubMed
10.
Zurück zum Zitat Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y (1982) Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res 42:4730–4733PubMed Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y (1982) Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res 42:4730–4733PubMed
11.
Zurück zum Zitat Heiduschka G, Lill C, Schneider S et al (2014) The effect of cilengitide in combination with irradiation and chemotherapy in head and neck squamous cell carcinoma cell lines. Strahlenther Onkol 190:472–479CrossRefPubMed Heiduschka G, Lill C, Schneider S et al (2014) The effect of cilengitide in combination with irradiation and chemotherapy in head and neck squamous cell carcinoma cell lines. Strahlenther Onkol 190:472–479CrossRefPubMed
12.
Zurück zum Zitat Heiduschka G, Erovic BM, Vormittag L et al (2009) 7beta-hydroxycholesterol induces apoptosis and regulates cyclooxygenase 2 in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 135:261–267CrossRefPubMed Heiduschka G, Erovic BM, Vormittag L et al (2009) 7beta-hydroxycholesterol induces apoptosis and regulates cyclooxygenase 2 in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 135:261–267CrossRefPubMed
13.
Zurück zum Zitat Denk DM, Heinzl H, Franz P, Ehrenberger K (1997) Caroverine in tinnitus treatment. A placebo-controlled blind study. Acta Otolaryngol 117:825–830CrossRefPubMed Denk DM, Heinzl H, Franz P, Ehrenberger K (1997) Caroverine in tinnitus treatment. A placebo-controlled blind study. Acta Otolaryngol 117:825–830CrossRefPubMed
14.
Zurück zum Zitat Domeisen H, Hotz MA, Häusler R (1998) Caroverine in tinnitus treatment. Acta Otolaryngol 118:606–608CrossRefPubMed Domeisen H, Hotz MA, Häusler R (1998) Caroverine in tinnitus treatment. Acta Otolaryngol 118:606–608CrossRefPubMed
15.
Zurück zum Zitat Geretsegger C, Fartacek R (1998) Infusional high-dose application of the calcium-channel-blocking and antiglutamatergic agent caroverine in the treatment of alcohol withdrawal (DSM-III-R 291.80). Eur Neuropsychopharmacol 8:191–194CrossRefPubMed Geretsegger C, Fartacek R (1998) Infusional high-dose application of the calcium-channel-blocking and antiglutamatergic agent caroverine in the treatment of alcohol withdrawal (DSM-III-R 291.80). Eur Neuropsychopharmacol 8:191–194CrossRefPubMed
16.
Zurück zum Zitat Rodrigues FAR, Bomfim IDS, Cavalcanti BC et al (2014) Design, synthesis and biological evaluation of (E)-2-(2-arylhydrazinyl)quinoxalines, a promising and potent new class of anticancer agents. Bioorg Med Chem Lett 24:934–939CrossRefPubMed Rodrigues FAR, Bomfim IDS, Cavalcanti BC et al (2014) Design, synthesis and biological evaluation of (E)-2-(2-arylhydrazinyl)quinoxalines, a promising and potent new class of anticancer agents. Bioorg Med Chem Lett 24:934–939CrossRefPubMed
17.
Zurück zum Zitat Lee SH, Kim N, Kim SJ, Song J, Gong YD, Kim SY (2013) Anti-cancer effect of a quinoxaline derivative GK13 as a transglutaminase 2 inhibitor. J Cancer Res Clin Oncol 139:1279–1294CrossRefPubMed Lee SH, Kim N, Kim SJ, Song J, Gong YD, Kim SY (2013) Anti-cancer effect of a quinoxaline derivative GK13 as a transglutaminase 2 inhibitor. J Cancer Res Clin Oncol 139:1279–1294CrossRefPubMed
18.
Zurück zum Zitat Ghattass K, El-Sitt S, Zibara K, Rayes S, Haddadin MJ, El-Sabban M, Gali-Muhtasib H (2014) The quinoxaline di-N-oxide DCQ blocks breast cancer metastasis in vitro and in vivo by targeting the hypoxia inducible factor-1 pathway. Mol Cancer 13:12PubMedCentralCrossRefPubMed Ghattass K, El-Sitt S, Zibara K, Rayes S, Haddadin MJ, El-Sabban M, Gali-Muhtasib H (2014) The quinoxaline di-N-oxide DCQ blocks breast cancer metastasis in vitro and in vivo by targeting the hypoxia inducible factor-1 pathway. Mol Cancer 13:12PubMedCentralCrossRefPubMed
19.
Zurück zum Zitat Chaturvedi NK, Rajule RN, Shukla A et al (2013) Novel treatment for mantle cell lymphoma including therapy-resistant tumor by NF-κB and mTOR dual-targeting approach. Mol Cancer Ther 12:2006–2017PubMedCentralCrossRefPubMed Chaturvedi NK, Rajule RN, Shukla A et al (2013) Novel treatment for mantle cell lymphoma including therapy-resistant tumor by NF-κB and mTOR dual-targeting approach. Mol Cancer Ther 12:2006–2017PubMedCentralCrossRefPubMed
20.
Zurück zum Zitat Palanichamy K, Sreejayan N, Ontko AC (2012) Overcoming cisplatin resistance using gold(III) mimics: anticancer activity of novel gold(III) polypyridyl complexes. J Inorg Biochem 106:32–42CrossRefPubMed Palanichamy K, Sreejayan N, Ontko AC (2012) Overcoming cisplatin resistance using gold(III) mimics: anticancer activity of novel gold(III) polypyridyl complexes. J Inorg Biochem 106:32–42CrossRefPubMed
Metadaten
Titel
Assessment of caroverine as a potential chemotherapeutical agent in HNSCC cell lines
verfasst von
Georg Haymerle
Dietmar Thurnher
Lorenz Kadletz
Isabella Stanisz
Markus Brunner
Ulana Kotowski
Elisabeth Enzenhofer
Gregor Heiduschka
Publikationsdatum
01.11.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
European Archives of Oto-Rhino-Laryngology / Ausgabe 11/2015
Print ISSN: 0937-4477
Elektronische ISSN: 1434-4726
DOI
https://doi.org/10.1007/s00405-014-3364-0

Weitere Artikel der Ausgabe 11/2015

European Archives of Oto-Rhino-Laryngology 11/2015 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

29.05.2024 Hörstörungen Nachrichten

Hört jemand im Alter schlecht, nimmt das Hirn- und Hippocampusvolumen besonders schnell ab, was auch mit einem beschleunigten kognitiven Abbau einhergeht. Und diese Prozesse scheinen sich unabhängig von der Amyloidablagerung zu ereignen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.